

BACIL PHARMA LIMITED

Regd. Off.: 71, LAXMI BUILDING, 4TH FLOOR, SIR P. M. ROAD, FORT, MUMBAI - 400 001.
Email ID: bacilpha@yahoo.com CIN: L24200MH1987PLC043427, Tel.: 22618452/22661541, Tel/Fax: 22618327

14th August, 2018

To
Department of Corporate Service
Corporate Relation Department
Bombay Stock Exchange Ltd.,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

BSE Script Code: 524516

Subject : Unaudited Financial Results for the Quarter ended 30th June, 2018

Dear Sir/Madam,


Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit Un-audited Financial Results of the Company for the Quarter ended 30th June, 2018 along with Statutory Auditors' Limited Review Report duly approved by the Board of Directors at its meeting held today i.e. 14th August, 2018.

The Board Meeting was concluded at 6:30 pm.

You are hereby requested to take the same on records.

Thanking You

Yours Faithfully
For **BACIL PHARMA LIMITED**


Prakash Shah
Director



Enclosure: As above

BACIL PHARMA LIMITED

CIN:L24200MH1987PLC043427

UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE 2018

(Amount in Lacs)

Sr. No.	Particulars	Quarter ended			Year ended
		30/6/18	31/3/18	30/6/17	31/3/18
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations				
	Other income	2.27	1.45	17.99	27.41
	Total revenue	2.27	1.45	17.99	27.41
2	Expenses				
	Employee benefits expense	2.36	4.82		12.61
	Depreciation and amortization expense	0.22	0.57	0.11	1.02
	Other expenses	9.14	6.34	5.22	19.44
	Total expenses	11.72	11.73	5.33	33.07
3	Profit before exceptional items and tax	(9.45)	(10.28)	12.66	(5.66)
	Exceptional items		369.48		369.48
	Profit / (Loss) from ordinary activities before tax	(9.45)	(379.76)	12.66	(375.14)
4	Tax expense:				
	(1) Current tax	-	-	-	-
	(2) Earlier year's Tax	-	-	-	-
	(3) Deferred tax	(0.03)	2.43	-	(0.14)
5	Profit/(Loss) from ordinary activities after tax	(9.42)	(382.19)	12.66	(375.00)
6	Other Comprehensive Income (OCI)				
	<u>Item that will not be reclassified to profit or loss</u>				
	Gain/(Loss) on recognised on fair valuation of Financial Assets	(16.86)	(49.35)	(12.68)	(56.32)
	Income tax relating to these items	4.34	11.48	3.92	11.48
	Total Other Comprehensive Income (OCI)	(12.52)	(37.87)	(8.76)	(44.84)
	Profit/(Loss) for the Period	(21.93)	(420.06)	3.90	(419.84)
	Paid up Equity Share Capital (Face Value of Rs. 10 each)	589.00	589.00	589.00	589.00
7	Earning Per Share (EPS) (Not annualised)				
	(1) Basic	(0.16)	(6.49)	0.22	(6.37)
	(2) Diluted	(0.16)	(6.49)	0.22	(6.37)

Notes:

- 1 The Above Financial Results were reviewed by the audit committee of the board on 14th August, 2018 and approved by the Board of Directors of the company at their meeting held on same date. The Statutory auditor have expressed an unmodified opinion. The review report has been filled with stock exchange and is available on the company's website. The Financial results have been prepared in accordance with Ind As notified under the companies (Accounting Standards) Rule 2015.
- 2 The figures of the fourth quarter ended 31st March, 2018 are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the quarter ended of the relevant financial year. Also the figures upto the quarter ended were only reviewed and not subjected to audit.
- 3 Exceptional item of Rs.369.48 lacs for the quarter & year ended 31st March 2018 represents diminution in the value of "Fixed Assets held for sale" on account of fair value recognition.
- 4 The company has adopted Indian Accounting Standard (Ind AS) effective from 1st April' 2017 (Transition date being 1st April' 2016) and accordingly the financial results for the quarter 30th June 2018 have been prepared in accordance with the recognition and measurement principles laid down in Ind As-34 Interim Financial Reporting prescribed under section 133 of the Companies Act' 2013.
- 5 Previous quarter figures have been regrouped /reclassified wherever necessary, to make them comparable.

For BACIL PHARMA LIMITED

Director



Place: Mumbai

Dated: 14th August 2018



Laxmikant Kabra & Co.

Chartered Accountants


INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT

TO,

THE BOARD OF DIRECTORS OF BACIL PHARMA LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Bacil Pharma Limited** ("the Company") for the quarter ended June 30, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Read with SEBI circular number CIR/CFD/FAC/62/2016 dated 5 July 2016. Attention is drawn to the fact that the figures of the fourth quarter ended March 31, 2018 are the balancing figures between audited figures in respect of the full financial year and published year to date figures up to the quarter ended of the relevant financial year. Also the figures up to the quarter ended were only reviewed and not subjected to audit. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial information performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the applicable Indian Accounting Standards (Ind AS) as prescribed under section 133 of Companies Act, 2013 read with rules issued there under and other recognised accounting practices and principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation And Disclosure Requirements) Regulation, 2015 read with SEBI circular number CIR/CFD/FAC/62/2016 dated 5th July 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.
4. We draw attention to the fact that figures for the corresponding quarter ended June 30, 2017 and year ended March 31, 2017 included in the statement are based on the previously issued financial results that were audited by the predecessor auditors vide their unmodified audit opinion dated 30th May, 2017.

For Laxmikant Kabra & Co.
Chartered Accountants



(CA Alok Kabra)

Partner

Membership No.: 179964

(Firm Registration No.: 117183W)



Place: Thane,

Date: 14th August, 2018